In Vitro Characterization and in Vivo Effectiveness of Ebola Virus Specific Equine Polyclonal F(ab′)2

Trina Racine, Mélanie Denizot, Delphine Pannetier, Ludovic Nguyen, Anaïs Pasquier, Hervé Raoul, Jean François Saluzzo, Gary Kobinger, Francisco Veas, Cécile H. Herbreteau

Research output: Contribution to journalArticlepeer-review

Abstract

There is no vaccine or approved therapy against lethal Ebola virus (EBOV). We investigated a proven technology platform to produce polyclonal IgG fragments, F(ab′)2, against EBOV. Horses immunized with nanoparticles harboring surface glycoprotein trimers of EBOV-Zaire/Makona produced anti-Ebola IgG polyclonal antibodies with high neutralization activity. Highly purified equine anti-Ebola F(ab′)2 showed strong cross-neutralization of 2 Zaire EBOV strains (Gabon 2001 and Makona) and in vivo 3 or 5 daily F(ab′)2 intraperitoneal injections provided 100% protection to BALB/c mice against lethal EBOV challenge. Rapid preparation of purified equine anti-Ebola F(ab′)2 offers a potentially efficient therapeutic approach against EBOV disease in humans.

Original languageEnglish (US)
Article numberjiz068
Pages (from-to)41-45
Number of pages5
JournalJournal of Infectious Diseases
Volume220
Issue number1
DOIs
StatePublished - Jun 5 2019
Externally publishedYes

Keywords

  • Ebola
  • F(ab′) fragments
  • equine
  • immunoglobulins

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'In Vitro Characterization and in Vivo Effectiveness of Ebola Virus Specific Equine Polyclonal F(ab′)2'. Together they form a unique fingerprint.

Cite this